416
Participants
Start Date
October 31, 2016
Primary Completion Date
June 6, 2024
Study Completion Date
June 30, 2024
Antiarrythmic Drug Therapy
Patients will be prescribed antiarrhythmic drugs (either amiodarone or sotalol based on specific clinical presentation, including medical history, functional class, ejection fraction, and renal function.)
Catheter ablation
Intracardiac electrode catheters are placed via central vasculature to identify myocardial scar, and surviving conduction channels within the scar which form the substrate for ventricular tachycardia. Radiofrequency energy is applied to these sites, interrupting the VT circuits.
Hopitaux de Bordeaux, Bordeaux
Vanderbilt University Hospital, Nashville
CHU - University Hospital Nancy, Nancy
Hartford General Hospital, Hartford
Foothills Hospital, Calgary
University of Alberta Hospital, Edmonton
Interior Health Authority, Kelowna
St. Paul's Hospital, Vancouver
Royal Jubilee Hospital, Victoria
Nova Scotia Health Authority, Halifax
Hamilton Health Sciences Center, Hamilton
Queen's University Health Sciences Centre, Kingston
St. Mary's Hospital, Kitchener
London Health Sciences Centre, London
University of Ottawa Heart Institute, Ottawa
St. Michael's Hospital, Toronto
Montreal Heart Institute, Montreal
Centre Hospitalier de l'Universitaire de Montreal, Montreal
McGill University Health Center, Montreal
Sacre-Coeur Hospital, Montreal
Institut Universitaire de cardiologie et pneumologie de Quebec - Laval University Hosptial, Québec
Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke
Collaborators (2)
Heart and Stroke Foundation of Canada
OTHER
Abbott Medical Devices
INDUSTRY
Biosense Webster, Inc.
INDUSTRY
Ottawa Heart Institute Research Corporation
OTHER
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
Cardiac Arrhythmia Network of Canada
OTHER
Abbott
INDUSTRY
Nova Scotia Health Authority
OTHER
John Sapp
OTHER